Illumina said after the close of the market on Thursday that its first quarter revenues rose 12 percent year over year.

The US Food and Drug Administration said on Wednesday it has issued de novo classification to Fujirebio Diagnostics' Lumipulse G β-Amyloid Ratio (1-42/1-40) test, allowing the company to market it as a tool for diagnosing Alzheimer's disease.

On April 20, Fapon Biotech Inc. and Guomao Health reached a strategic cooperation intention for IVD ecological open platform. The signing ceremony of cooperation between DIAN Diagnostics Group Co., Ltd. and Taizhou Enze Medical Center was held in Taizhou Hospital.

BioMérieux said on Wednesday that its BioFire Joint Infection (JI) Panel has received de novo authorization from the US Food and Drug Administration.

Abbott announced on Wednesday that its multiplex sexually transmitted infection panel has received clearance from the US Food and Drug Administration.

On April 28, YHLO (688575. SH) released its annual performance report for 2021. From January 1 to December 31, 2021, the company achieved an operating revenue of 1.178 billion CNY, a year-on-year increase of 17.91%, a net profit of 205 million CNY, a year-on-year decrease of 2.75%.

Thermo Fisher Scientific on Thursday morning reported a 19 percent increase in first quarter revenues, driven by growth in most of its business segments.

Pfizer and BioNTech have submitted an application for Emergency Use Authorization for a COVID-19 vaccine booster dose in young children.

Recently, the first 5G digital mobile hospital in China jointly built by Roche Diagnostics, GE Healthcare, Boao Yiling Medical Group and Yutong Group was officially delivered.

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2022 Prix Galien International Awards.

MDxHealth reported after the close of the market Wednesday a 21 percent increase in first quarter 2022 sales.

Qiagen on Tuesday afternoon reported strong first quarter revenues that blew by Wall Street estimates, driven by growth in its molecular diagnostics business.

Exact Sciences reported after the close of the market on Tuesday that its first quarter revenues rose 21 percent year over year.

On April 27, Autobio, BSBE, Easy Diagnosis, Medicalsystem, Dian Diagnostics, Hybribio and Kingmed released 2022 Q1 report.

Wondfo, BGI, Leadman, Sinocare, ACROBiosystems, NanoMicro released 2022 Q1 Report